Cancer and the Immune System: The History and Background of Immunotherapy
This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones. Published data and peer reviewed publications/manuscripts, and textbook chapters. Science has provided a greater understanding of the interactions bet...
Saved in:
| Published in: | Seminars in oncology nursing Vol. 35; no. 5; p. 150923 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01.10.2019
|
| Subjects: | |
| ISSN: | 0749-2081, 1878-3449, 1878-3449 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.
Published data and peer reviewed publications/manuscripts, and textbook chapters.
Science has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies.
Nurses’ knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer. |
|---|---|
| AbstractList | This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.
Published data and peer reviewed publications/manuscripts, and textbook chapters.
Science has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies.
Nurses' knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer. This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.OBJECTIVEThis article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.Published data and peer reviewed publications/manuscripts, and textbook chapters.DATA SOURCESPublished data and peer reviewed publications/manuscripts, and textbook chapters.Science has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies.CONCLUSIONScience has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies.Nurses' knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer.IMPLICATIONS FOR NURSING PRACTICENurses' knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer. |
| ArticleNumber | 150923 |
| Author | Ustoyev, Yelena Abbott, Maura |
| Author_xml | – sequence: 1 givenname: Maura surname: Abbott fullname: Abbott, Maura email: ma3425@cumc.columbia.edu organization: Columbia University School of Nursing, New York, NY – sequence: 2 givenname: Yelena surname: Ustoyev fullname: Ustoyev, Yelena organization: Columbia University Irving Medical Center, New York, NY |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31526550$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc9P2zAUgK0JNArbXzBpynGXBP9I4rxJO4xqQKVKHGBny3Vehktjd7aD1P9-LmUcOMDJlvV9T3qfT8mR8w4J-cJoxShrz9dV9M64ilMGFe0qSvkHMmOd7EpR13BEZlTWUHLasRNyGuM6A9BS-EhOBGt42zR0RhZz7QyGQru-SPdYLMZxcljc7mLC8Xtxl5-ubUw-7J6QC20e_gQ_5asfDrDPWtDb3SdyPOhNxM_P5xn5ffnrbn5dLm-uFvOfy9LUvEllhyvGBa1BrwyT0EoOIPqmb6TUK1kLMQwoNGhumOHQc4kA9QCspVT0BlGckW-Hudvg_04YkxptNLjZaId-iopz4NCJrpEZ_fqMTqsRe7UNdtRhp_6vnwFxAEzwMQYcXhBG1T6yWqunyGofWdFO5YbZgleWsUkn610K2m7ecX8cXMyJHi0GFY3F_AW9DWiS6r190_8HlpaX4Q |
| CitedBy_id | crossref_primary_10_1016_j_canlet_2022_215834 crossref_primary_10_1016_j_jff_2023_105560 crossref_primary_10_1002_iub_2299 crossref_primary_10_3389_fimmu_2022_1017120 crossref_primary_10_1007_s11912_023_01486_2 crossref_primary_10_1016_j_tips_2023_09_008 crossref_primary_10_3390_cancers14225678 crossref_primary_10_3390_ijms25126480 crossref_primary_10_1155_2023_6831695 crossref_primary_10_3389_fimmu_2024_1418286 crossref_primary_10_1186_s40001_023_01468_x crossref_primary_10_1016_j_bbcan_2023_189021 crossref_primary_10_3390_cells10102672 crossref_primary_10_1007_s11255_024_04244_w crossref_primary_10_2147_TCRM_S479686 crossref_primary_10_3389_fimmu_2024_1481753 crossref_primary_10_1155_2022_7730433 crossref_primary_10_3389_fchem_2021_629635 crossref_primary_10_3389_fonc_2022_844666 crossref_primary_10_3389_fphar_2023_1169608 crossref_primary_10_1007_s10529_023_03461_0 crossref_primary_10_1007_s11033_023_08946_9 crossref_primary_10_1007_s44411_025_00266_7 crossref_primary_10_1016_j_procs_2025_03_039 crossref_primary_10_1039_D2NR02994D crossref_primary_10_1186_s13058_024_01928_0 crossref_primary_10_3390_ijms232213696 crossref_primary_10_3390_cancers14204968 crossref_primary_10_1002_cnr2_70087 crossref_primary_10_1038_s41591_025_03615_9 crossref_primary_10_3390_molecules29122770 crossref_primary_10_1016_j_fbio_2025_107033 crossref_primary_10_3389_fimmu_2021_790674 crossref_primary_10_3390_cells13100864 crossref_primary_10_1007_s12032_023_02060_3 crossref_primary_10_3171_2021_11_FOCUS21571 crossref_primary_10_1002_mco2_210 crossref_primary_10_1007_s00384_024_04790_w crossref_primary_10_3390_cancers13133228 crossref_primary_10_1007_s12272_021_01355_1 crossref_primary_10_1186_s12943_021_01406_7 crossref_primary_10_3389_fimmu_2021_654877 crossref_primary_10_3389_fcimb_2024_1460604 crossref_primary_10_1002_smll_202307111 crossref_primary_10_3390_vaccines13010064 crossref_primary_10_1097_COC_0000000000001166 crossref_primary_10_1002_VIW_20230117 crossref_primary_10_1136_jim_2021_002159 crossref_primary_10_1111_jcmm_70675 crossref_primary_10_1016_j_cclet_2023_108224 crossref_primary_10_1002_chem_202403508 crossref_primary_10_1016_j_jconrel_2024_12_010 crossref_primary_10_3389_fphar_2023_1238841 crossref_primary_10_3390_pharmaceutics15010148 crossref_primary_10_1177_1043454220966590 crossref_primary_10_1039_D5AN00105F crossref_primary_10_1155_2023_4522045 crossref_primary_10_1186_s12935_023_02872_3 crossref_primary_10_3389_fonc_2025_1606286 crossref_primary_10_3390_cancers13153789 crossref_primary_10_1016_j_ccr_2023_215654 crossref_primary_10_1080_07853890_2023_2215543 crossref_primary_10_3390_pathogens13100828 crossref_primary_10_3389_fgene_2022_1016449 crossref_primary_10_1038_s41392_021_00729_7 crossref_primary_10_1155_2024_8481761 crossref_primary_10_3390_cancers13246293 crossref_primary_10_3389_fonc_2023_1266514 crossref_primary_10_1016_j_prp_2022_154295 crossref_primary_10_1002_jgm_3590 crossref_primary_10_1016_j_ijbiomac_2024_130032 crossref_primary_10_1111_cns_14315 crossref_primary_10_1038_s41598_024_70223_x crossref_primary_10_2217_imt_2021_0316 crossref_primary_10_1080_07853890_2022_2124449 crossref_primary_10_3390_ijms231810494 crossref_primary_10_1016_j_drudis_2025_104436 crossref_primary_10_3389_fimmu_2020_583287 crossref_primary_10_3390_jcm12216812 crossref_primary_10_1007_s12012_025_10038_y crossref_primary_10_1177_00045632241312629 crossref_primary_10_3390_cancers15215143 crossref_primary_10_3389_fonc_2023_1287555 crossref_primary_10_3390_biology12030376 crossref_primary_10_3390_life12111807 crossref_primary_10_1111_nyas_14526 crossref_primary_10_1007_s12072_023_10593_y crossref_primary_10_1155_2022_5423694 crossref_primary_10_1016_j_heliyon_2024_e24559 crossref_primary_10_3390_ijms25126444 crossref_primary_10_1002_jcla_25020 crossref_primary_10_1002_mabi_202100356 crossref_primary_10_1016_j_lfs_2023_121917 crossref_primary_10_1155_2022_8423173 crossref_primary_10_1016_j_liver_2025_100285 crossref_primary_10_3389_fimmu_2024_1383978 crossref_primary_10_1007_s11033_022_07765_8 crossref_primary_10_1111_hel_12999 crossref_primary_10_1007_s12672_025_03288_3 crossref_primary_10_3389_fmolb_2024_1361377 crossref_primary_10_1007_s12013_025_01830_2 crossref_primary_10_1155_2022_3660110 crossref_primary_10_3390_biomedicines13061356 crossref_primary_10_1007_s11864_025_01340_6 crossref_primary_10_1080_17460441_2022_2114454 crossref_primary_10_3390_cancers17111847 crossref_primary_10_1002_wnan_1870 crossref_primary_10_1007_s00705_024_06133_0 crossref_primary_10_1155_2022_6947652 crossref_primary_10_1016_j_ijpharm_2023_123729 crossref_primary_10_1002_stem_3391 crossref_primary_10_1016_j_critrevonc_2023_104225 crossref_primary_10_3390_ijms24065268 crossref_primary_10_1007_s00210_024_03258_6 crossref_primary_10_1007_s11033_023_09079_9 crossref_primary_10_1155_2022_1463316 crossref_primary_10_3390_cancers14215414 crossref_primary_10_1002_adhm_202404795 crossref_primary_10_1080_14712598_2024_2431088 crossref_primary_10_3390_cancers17050880 crossref_primary_10_3389_fimmu_2023_1200245 crossref_primary_10_1186_s12943_025_02305_x crossref_primary_10_3390_ijms23010488 crossref_primary_10_3389_fimmu_2024_1375013 crossref_primary_10_1038_s41571_025_01059_1 crossref_primary_10_1007_s12033_022_00601_1 crossref_primary_10_1093_ckj_sfac194 crossref_primary_10_1016_j_biopha_2023_115136 crossref_primary_10_1016_j_prp_2024_155252 crossref_primary_10_3389_fendo_2020_608422 crossref_primary_10_1002_mas_21905 crossref_primary_10_1038_s41598_023_44397_9 crossref_primary_10_3390_vetsci9070327 crossref_primary_10_1007_s10142_024_01445_5 crossref_primary_10_1038_s41419_024_06837_w crossref_primary_10_3390_cancers15235589 crossref_primary_10_1186_s12957_022_02703_1 crossref_primary_10_1055_s_0045_1802321 crossref_primary_10_3390_cancers15215299 crossref_primary_10_1039_D1NH00179E crossref_primary_10_1007_s00262_024_03684_8 crossref_primary_10_1080_14737140_2023_2245567 crossref_primary_10_1007_s10585_024_10322_1 crossref_primary_10_1016_j_isci_2024_110587 crossref_primary_10_1002_tox_24040 crossref_primary_10_1155_2022_8809956 crossref_primary_10_1016_j_canlet_2024_216817 crossref_primary_10_1016_j_bbcan_2024_189170 crossref_primary_10_3389_fmolb_2023_1190669 crossref_primary_10_1007_s12032_023_02023_8 crossref_primary_10_1002_SMMD_20230035 crossref_primary_10_3389_fimmu_2024_1490260 crossref_primary_10_1186_s40364_022_00364_6 crossref_primary_10_1155_2022_4662874 crossref_primary_10_3390_cancers14174142 crossref_primary_10_3389_fphar_2024_1283465 crossref_primary_10_1021_acs_jmedchem_4c02206 crossref_primary_10_1007_s12672_025_03275_8 crossref_primary_10_1007_s12011_023_03668_2 crossref_primary_10_4103_2221_1691_290134 crossref_primary_10_3389_fimmu_2024_1470468 crossref_primary_10_3389_fcell_2021_739161 crossref_primary_10_1097_CJI_0000000000000545 crossref_primary_10_2147_IJN_S529003 crossref_primary_10_1007_s12672_023_00670_x crossref_primary_10_1080_15384047_2025_2508535 crossref_primary_10_1371_journal_pone_0332747 crossref_primary_10_1002_cam4_6989 crossref_primary_10_3389_fimmu_2022_1037808 crossref_primary_10_1016_j_abb_2022_109168 crossref_primary_10_3390_biomedicines11051292 crossref_primary_10_1093_jleuko_qiae030 crossref_primary_10_3389_fonc_2023_1327147 crossref_primary_10_3390_cancers16203542 crossref_primary_10_1016_j_addr_2023_115110 crossref_primary_10_1016_j_ymthe_2025_07_030 crossref_primary_10_3389_fimmu_2023_1330099 crossref_primary_10_1016_j_tranon_2021_101166 crossref_primary_10_1172_JCI170503 crossref_primary_10_7759_cureus_54487 crossref_primary_10_1016_j_lfs_2022_120573 crossref_primary_10_3390_biomedicines11020308 crossref_primary_10_1002_ctm2_70020 crossref_primary_10_3390_diagnostics13020302 crossref_primary_10_3389_fgene_2022_788580 crossref_primary_10_1038_s41598_023_28305_9 crossref_primary_10_3390_cancers13236067 crossref_primary_10_3389_fimmu_2023_1213467 crossref_primary_10_3390_ijms232416116 crossref_primary_10_3390_biology14030253 crossref_primary_10_3390_cancers15245786 crossref_primary_10_1002_EXP_20220173 crossref_primary_10_3389_fonc_2021_612952 crossref_primary_10_3389_fimmu_2024_1327898 crossref_primary_10_1016_j_jconrel_2023_01_076 crossref_primary_10_1002_btm2_10482 crossref_primary_10_1016_j_bcp_2023_115460 crossref_primary_10_1016_j_bbcan_2025_189415 crossref_primary_10_1016_j_ymeth_2020_11_005 crossref_primary_10_3390_cells12060830 crossref_primary_10_1016_j_arr_2025_102820 crossref_primary_10_3390_vaccines11081354 crossref_primary_10_1016_j_cpt_2023_09_001 crossref_primary_10_1093_immadv_ltae005 crossref_primary_10_1016_j_cca_2022_06_009 crossref_primary_10_1177_10732748241302248 crossref_primary_10_1016_j_apsb_2024_03_004 crossref_primary_10_1016_j_jep_2022_115573 crossref_primary_10_1155_2022_7061263 crossref_primary_10_1155_2023_6563609 crossref_primary_10_3389_fgene_2021_616073 crossref_primary_10_1016_j_biomaterials_2024_122550 crossref_primary_10_1155_2022_8422339 crossref_primary_10_1007_s12672_024_01011_2 crossref_primary_10_1002_agt2_70080 crossref_primary_10_3389_fimmu_2024_1341390 crossref_primary_10_1097_CM9_0000000000002631 crossref_primary_10_1016_j_canlet_2024_216990 crossref_primary_10_3892_ol_2025_15237 crossref_primary_10_1038_s41564_024_01695_w crossref_primary_10_3390_diagnostics12020251 crossref_primary_10_1080_17474086_2022_2091542 crossref_primary_10_1016_j_jddst_2023_105050 crossref_primary_10_3390_biom15030357 crossref_primary_10_1016_j_cyto_2021_155760 crossref_primary_10_1016_j_biopha_2023_115048 crossref_primary_10_3389_fimmu_2022_927565 crossref_primary_10_14235_bas_galenos_2021_4790 crossref_primary_10_1002_adbi_202400720 crossref_primary_10_1016_j_cancergen_2025_03_004 crossref_primary_10_3390_brainsci11111529 crossref_primary_10_1093_bjd_ljad421 crossref_primary_10_3390_biology12121528 crossref_primary_10_1177_10781552251324896 crossref_primary_10_1016_j_intimp_2023_110807 crossref_primary_10_3390_cancers14194920 crossref_primary_10_1007_s40610_024_00161_0 crossref_primary_10_3389_fonc_2023_1170482 crossref_primary_10_3390_cells11030349 crossref_primary_10_1186_s12920_024_02082_4 crossref_primary_10_1007_s00520_023_08284_3 crossref_primary_10_1002_mabi_202000222 crossref_primary_10_1002_mco2_70015 crossref_primary_10_1016_j_lfs_2023_121997 crossref_primary_10_2147_DDDT_S374672 crossref_primary_10_3390_cancers16091674 crossref_primary_10_1177_1533033820980088 crossref_primary_10_1155_2024_1373659 crossref_primary_10_12968_hmed_2024_0375 crossref_primary_10_1515_oncologie_2023_0140 crossref_primary_10_56618_2071_2693_2023_15_4_200 crossref_primary_10_1021_acs_molpharmaceut_4c01502 crossref_primary_10_1080_19336950_2021_1968592 crossref_primary_10_3389_fgene_2022_1068462 crossref_primary_10_3390_pharmaceutics15082138 crossref_primary_10_3389_fcell_2024_1302490 crossref_primary_10_1016_j_canlet_2023_216219 crossref_primary_10_1002_jcp_30730 crossref_primary_10_1097_MD_0000000000030569 crossref_primary_10_3390_membranes12080738 crossref_primary_10_4103_abr_abr_101_24 crossref_primary_10_2217_fon_2020_0143 crossref_primary_10_1016_j_heliyon_2024_e35989 crossref_primary_10_1111_crj_70054 crossref_primary_10_3390_ijms25168924 crossref_primary_10_1007_s11154_023_09846_w crossref_primary_10_1016_j_ultrasmedbio_2024_09_008 crossref_primary_10_1002_cmdc_202300305 crossref_primary_10_1016_j_envres_2023_116751 crossref_primary_10_1016_j_jbiosc_2024_05_013 crossref_primary_10_3390_ijms252011091 crossref_primary_10_3389_fimmu_2021_737340 crossref_primary_10_1007_s12272_022_01397_z crossref_primary_10_1016_j_biomaterials_2023_122428 crossref_primary_10_3389_fimmu_2025_1518647 crossref_primary_10_3390_cancers15072009 crossref_primary_10_3390_cancers15092531 crossref_primary_10_3390_cells13060510 crossref_primary_10_1186_s12964_023_01425_5 crossref_primary_10_1126_scisignal_ads7889 crossref_primary_10_3389_fonc_2022_1036477 crossref_primary_10_1016_j_apsb_2022_11_007 crossref_primary_10_3390_biology12050697 crossref_primary_10_1016_j_heliyon_2024_e37213 crossref_primary_10_1002_msp2_29 crossref_primary_10_1186_s12935_024_03295_4 crossref_primary_10_1016_j_bbcan_2023_188873 crossref_primary_10_3390_biomedicines12092038 crossref_primary_10_1002_adhm_202001415 crossref_primary_10_1016_j_bcp_2025_116803 crossref_primary_10_3892_ol_2023_13958 crossref_primary_10_4251_wjgo_v14_i1_19 crossref_primary_10_3390_curroncol32070392 crossref_primary_10_3389_fonc_2024_1391408 crossref_primary_10_1088_1361_6463_ad2832 crossref_primary_10_32604_biocell_2024_054879 crossref_primary_10_3389_fimmu_2022_1022420 crossref_primary_10_3389_fimmu_2022_925985 crossref_primary_10_1016_j_oraloncology_2022_106064 crossref_primary_10_3390_jcm11206154 crossref_primary_10_3390_cimb47060406 crossref_primary_10_3390_vetsci11120636 crossref_primary_10_3390_pharmaceutics14091762 crossref_primary_10_3389_fchem_2022_1031811 crossref_primary_10_3389_fimmu_2021_615930 crossref_primary_10_3390_cancers15071963 crossref_primary_10_3389_fimmu_2024_1322468 crossref_primary_10_1007_s13193_025_02383_9 crossref_primary_10_3389_fonc_2025_1534545 |
| Cites_doi | 10.1146/annurev-med-112311-083918 10.1126/science.1851332 10.1126/scitranslmed.3002842 10.1182/blood-2007-12-128843 10.1385/IR:32:1-3:231 10.1038/onc.2008.277 10.1158/2159-8290.CD-12-0548 10.1016/S0022-5347(17)58737-6 10.1056/NEJMoa1215134 10.1016/j.imlet.2014.05.010 10.1056/NEJM190802061580601 10.1188/17.CJON.S2.9-12 10.1053/j.seminoncol.2015.05.003 10.20517/2394-4722.2017.41 10.1038/nbt.2287 10.1016/j.immuni.2013.07.012 10.1016/j.immuni.2004.07.017 10.21037/cco.2018.04.04 10.1016/j.cytogfr.2009.07.004 10.1016/j.cell.2017.01.017 10.1038/ni1213 10.1016/j.cell.2011.02.013 10.1126/science.271.5256.1734 10.1111/cas.13027 10.1126/science.342.6165.1432 10.6004/jnccn.2015.0199 10.1126/science.1203486 10.3844/ajisp.2009.29.49 10.1038/nrc2628 10.1200/JCO.2014.56.2025 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.soncn.2019.08.002 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Nursing |
| EISSN | 1878-3449 |
| ExternalDocumentID | 31526550 10_1016_j_soncn_2019_08_002 S0749208119301056 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -ET .GJ .~1 07C 0R~ 123 1B1 1RT 1~. 1~5 2FS 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABSN AACTN AAEDT AAEDW AAGJQ AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFRF ABJNI ABLVK ABMAC ABMZM ABPPZ ABXDB ABYKQ ACDAQ ACGFO ACGFS ACJTP ACNCT ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AFDAS AFFNX AFKWA AFTJW AFXBA AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AISVY AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV COPKO CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FAFAN FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ H~9 IH2 IHE J1W J5H KOM LCYCR M27 M41 MO0 N4W N9A NAHTW O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SEL SES SEW SNC SND SNG SPCBC SSH SSZ T5K UKR UNMZH WOW WUQ YZZ ZGI ~G- 9DU AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGLDT AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c425t-8eb123049abc179672993d5d577ab7433ffe3a9a2c1c29d27e994f916003dcee3 |
| ISICitedReferencesCount | 352 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000493279100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0749-2081 1878-3449 |
| IngestDate | Thu Oct 02 09:46:15 EDT 2025 Wed Feb 19 02:31:03 EST 2025 Sat Nov 29 07:11:46 EST 2025 Tue Nov 18 21:52:28 EST 2025 Fri Feb 23 02:32:06 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Innate immunity Adaptive immunity History Cancer immunotherapy Immunotherapy history |
| Language | English |
| License | Copyright © 2019 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c425t-8eb123049abc179672993d5d577ab7433ffe3a9a2c1c29d27e994f916003dcee3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 31526550 |
| PQID | 2292983857 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2292983857 pubmed_primary_31526550 crossref_primary_10_1016_j_soncn_2019_08_002 crossref_citationtrail_10_1016_j_soncn_2019_08_002 elsevier_sciencedirect_doi_10_1016_j_soncn_2019_08_002 |
| PublicationCentury | 2000 |
| PublicationDate | October 2019 2019-10-00 20191001 |
| PublicationDateYYYYMMDD | 2019-10-01 |
| PublicationDate_xml | – month: 10 year: 2019 text: October 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Seminars in oncology nursing |
| PublicationTitleAlternate | Semin Oncol Nurs |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Dunn, Bruce, Ikeda, Old, Schreiber (bib0019) 2002; 3 Olszanski (bib0003) 2015; 13 Coley (bib0005) 1893; 105 Blair, Cook (bib0016) 2008; 27 O'Malley, Achinstein, Shear (bib0021) 1962; 29 Kochenderfer, Dudley, Kassim (bib0034) 2015; 33 Kalos, Levine, Porter (bib0032) 2011; 3 Russell, Peng, Bell (bib0027) 2012; 30 Leach, Krummel, Allison (bib0025) 1992; 271 Sharma, Hu-Lieskovan, Wargo, Ribas (bib0008) 2017; 168 Ribatti (bib0024) 2014; 161 Dunn, Bruce, Sheehan (bib0011) 2005; 6 Coley (bib0006) 1908; 158 Martuza, Malick, Markert, Ruffner, Coen (bib0029) 1991; 252 Couzin-Frankel (bib0001) 2013; 324 Decker, Safdar (bib0007) 2009; 20 Block, Markovic (bib0017) 2009; 5 Dunn, Old, Schreiber (bib0018) 2004; 21 Lizée, Overwijk, Radvanyi, Gao, Sharma, Hwu (bib0020) 2013; 64 Schreiber, Old, Smyth (bib0035) 2011; 331 Fukuhara, Ino, Todo (bib0026) 2016; 107 Russell, Peng (bib0028) 2018; 7 Ginex, Brassil, Ely (bib0004) 2017; 2 Chen, Mellman (bib0015) 2013; 39 Pardoll (bib0012) 2015; 42 Balkwill (bib0022) 2009; 9 Morales, Eidinger, Bruce (bib0023) 1976; 116 Sadelain, Brentjens, Rivière (bib0030) 2013; 3 Dunn, Ikeda, Bruce (bib0010) 2005; 32 Gasparri, Ruscito, Taghavi (bib0009) 2017 Oiseth, Aziz (bib0013) 2017; 3 Hanahan, Weinberg (bib0014) 2011; 144 Till, Jensen, Wang (bib0031) 2008; 112 Grupp, Kalos, Barrett (bib0033) 2013; 368 Riedel (bib0002) 2005; 18 Hanahan (10.1016/j.soncn.2019.08.002_bib0014) 2011; 144 Block (10.1016/j.soncn.2019.08.002_bib0017) 2009; 5 O'Malley (10.1016/j.soncn.2019.08.002_bib0021) 1962; 29 Leach (10.1016/j.soncn.2019.08.002_bib0025) 1992; 271 Grupp (10.1016/j.soncn.2019.08.002_bib0033) 2013; 368 Russell (10.1016/j.soncn.2019.08.002_bib0027) 2012; 30 Sadelain (10.1016/j.soncn.2019.08.002_bib0030) 2013; 3 Ginex (10.1016/j.soncn.2019.08.002_bib0004) 2017; 2 Dunn (10.1016/j.soncn.2019.08.002_bib0011) 2005; 6 Ribatti (10.1016/j.soncn.2019.08.002_bib0024) 2014; 161 Kochenderfer (10.1016/j.soncn.2019.08.002_bib0034) 2015; 33 Couzin-Frankel (10.1016/j.soncn.2019.08.002_bib0001) 2013; 324 Martuza (10.1016/j.soncn.2019.08.002_bib0029) 1991; 252 Coley (10.1016/j.soncn.2019.08.002_bib0005) 1893; 105 Till (10.1016/j.soncn.2019.08.002_bib0031) 2008; 112 Lizée (10.1016/j.soncn.2019.08.002_bib0020) 2013; 64 Blair (10.1016/j.soncn.2019.08.002_bib0016) 2008; 27 Russell (10.1016/j.soncn.2019.08.002_bib0028) 2018; 7 Decker (10.1016/j.soncn.2019.08.002_bib0007) 2009; 20 Oiseth (10.1016/j.soncn.2019.08.002_bib0013) 2017; 3 Dunn (10.1016/j.soncn.2019.08.002_bib0019) 2002; 3 Riedel (10.1016/j.soncn.2019.08.002_bib0002) 2005; 18 Dunn (10.1016/j.soncn.2019.08.002_bib0010) 2005; 32 Fukuhara (10.1016/j.soncn.2019.08.002_bib0026) 2016; 107 Dunn (10.1016/j.soncn.2019.08.002_bib0018) 2004; 21 Kalos (10.1016/j.soncn.2019.08.002_bib0032) 2011; 3 Coley (10.1016/j.soncn.2019.08.002_bib0006) 1908; 158 Balkwill (10.1016/j.soncn.2019.08.002_bib0022) 2009; 9 Chen (10.1016/j.soncn.2019.08.002_bib0015) 2013; 39 Schreiber (10.1016/j.soncn.2019.08.002_bib0035) 2011; 331 Gasparri (10.1016/j.soncn.2019.08.002_bib0009) 2017 Pardoll (10.1016/j.soncn.2019.08.002_bib0012) 2015; 42 Morales (10.1016/j.soncn.2019.08.002_bib0023) 1976; 116 Sharma (10.1016/j.soncn.2019.08.002_bib0008) 2017; 168 Olszanski (10.1016/j.soncn.2019.08.002_bib0003) 2015; 13 |
| References_xml | – volume: 168 start-page: 707 year: 2017 end-page: 723 ident: bib0008 article-title: Primary, adaptive, and acquired resistance to cancer immunity publication-title: Cell – volume: 116 start-page: 180 year: 1976 end-page: 182 ident: bib0023 article-title: Intracavity Bacillus Calmette-Guerin in the treatment of superficial bladder tumors publication-title: J Urol – start-page: 193 year: 2017 end-page: 204 ident: bib0009 article-title: The immunobiology of cancer: from tumor escape to cancer immunoediting towards immunotherapy in gynecologic oncology publication-title: Molecular oncology: underlying mechanisms and translational advancements – volume: 32 start-page: 231 year: 2005 end-page: 245 ident: bib0010 article-title: Interferon gamma and cancer immunoediting publication-title: Immunol Res – volume: 3 start-page: 388 year: 2013 end-page: 398 ident: bib0030 article-title: The basic principles of chimeric antigen receptor design publication-title: Cancer Discov – volume: 3 start-page: 991 year: 2002 end-page: 998 ident: bib0019 article-title: Cancer immunoediting: from immunosurveillance to tumor escape publication-title: Nature – volume: 252 start-page: 854 year: 1991 end-page: 856 ident: bib0029 article-title: Experimental therapy of human glioma by means of a genetically engineered virus mutant publication-title: Science – volume: 161 start-page: 96 year: 2014 end-page: 99 ident: bib0024 article-title: From the discovery of monoclonal antibodies to their therapeutic application: an historical appraisal publication-title: Immunol Lett – volume: 20 start-page: 271 year: 2009 end-page: 281 ident: bib0007 article-title: Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited publication-title: Cytokine Growth Factor Rev – volume: 7 start-page: 16 year: 2018 ident: bib0028 article-title: The emerging role of oncolytic virus therapy against cancer publication-title: Chin Clin Oncol – volume: 2 start-page: 9 year: 2017 end-page: 15 ident: bib0004 article-title: Immunotherapy: exploring the state of the science publication-title: Clin J Oncol Nurs – volume: 39 start-page: 1 year: 2013 end-page: 10 ident: bib0015 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity – volume: 18 start-page: 21 year: 2005 end-page: 25 ident: bib0002 article-title: Edward Jenner and the history of smallpox and vaccination publication-title: Proc (Bay Univ Med Cent) – volume: 331 start-page: 1565 year: 2011 end-page: 1570 ident: bib0035 article-title: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion publication-title: Science – volume: 105 year: 1893 ident: bib0005 article-title: Treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases publication-title: Am J Med Sci – volume: 21 start-page: 137 year: 2004 end-page: 148 ident: bib0018 article-title: The immunobiology of cancer immunosurveillance and immunoediting publication-title: Immunity – volume: 13 start-page: 670 year: 2015 end-page: 672 ident: bib0003 article-title: Principles of immunotherapy publication-title: J Natl Comp Canc Netw – volume: 64 start-page: 71 year: 2013 end-page: 90 ident: bib0020 article-title: Harnessing the power of the immune system to target cancer publication-title: Annu Rev Med – volume: 9 start-page: 361 year: 2009 end-page: 371 ident: bib0022 article-title: Tumour necrosis factor and cancer publication-title: Nat Rev Cancer – volume: 29 start-page: 1169 year: 1962 end-page: 1175 ident: bib0021 article-title: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance publication-title: J Natl Cancer Inst – volume: 144 start-page: 646 year: 2011 end-page: 674 ident: bib0014 article-title: Hallmarks of cancer: the next generation publication-title: Cell – volume: 158 start-page: 175 year: 1908 end-page: 182 ident: bib0006 article-title: The treatment of sarcoma with the mixed toxins of erysipelas and bacillus prodigiosus publication-title: Boston Medical and Surgical Journal – volume: 6 start-page: 722 year: 2005 end-page: 729 ident: bib0011 article-title: A critical function for type I interferons in cancer immunoediting publication-title: Nat Immunol – volume: 3 start-page: 250 year: 2017 end-page: 261 ident: bib0013 article-title: Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead publication-title: J Cancer Metastasis Treat – volume: 30 start-page: 658 year: 2012 end-page: 670 ident: bib0027 article-title: Oncolytic virotherapy publication-title: Nat Biotechnol – volume: 368 start-page: 1509 year: 2013 end-page: 1518 ident: bib0033 article-title: Chimeric antigen receptor–modified T cells for acute lymphoid leukemia publication-title: N Engl J Med – volume: 324 start-page: 1432 year: 2013 end-page: 1433 ident: bib0001 article-title: Cancer Immunotherapy publication-title: Science – volume: 33 start-page: 540 year: 2015 end-page: 549 ident: bib0034 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J Clin Oncol – volume: 3 start-page: 95 year: 2011 ident: bib0032 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci Transl Med – volume: 5 start-page: 29 year: 2009 end-page: 49 ident: bib0017 article-title: The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion publication-title: Am J Immunol – volume: 42 start-page: 523 year: 2015 end-page: 538 ident: bib0012 article-title: Cancer and the immune system: basic concepts and targets for intervention publication-title: Semin Oncol – volume: 27 start-page: 5868 year: 2008 ident: bib0016 article-title: Cancer and the immune system: an overview publication-title: Oncogene – volume: 112 start-page: 2261 year: 2008 end-page: 2271 ident: bib0031 article-title: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells publication-title: Blood – volume: 271 start-page: 1734 year: 1992 end-page: 1736 ident: bib0025 article-title: Enhancement of anti-tumor immunity by CTLA-4 blockade publication-title: Science – volume: 107 start-page: 1373 year: 2016 end-page: 1379 ident: bib0026 article-title: Oncolytic virus therapy: a new era of cancer treatment at dawn publication-title: Cancer Sci – volume: 105 issue: 6 year: 1893 ident: 10.1016/j.soncn.2019.08.002_bib0005 article-title: Treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases publication-title: Am J Med Sci – volume: 64 start-page: 71 year: 2013 ident: 10.1016/j.soncn.2019.08.002_bib0020 article-title: Harnessing the power of the immune system to target cancer publication-title: Annu Rev Med doi: 10.1146/annurev-med-112311-083918 – volume: 252 start-page: 854 year: 1991 ident: 10.1016/j.soncn.2019.08.002_bib0029 article-title: Experimental therapy of human glioma by means of a genetically engineered virus mutant publication-title: Science doi: 10.1126/science.1851332 – volume: 3 start-page: 95 year: 2011 ident: 10.1016/j.soncn.2019.08.002_bib0032 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002842 – volume: 112 start-page: 2261 year: 2008 ident: 10.1016/j.soncn.2019.08.002_bib0031 article-title: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells publication-title: Blood doi: 10.1182/blood-2007-12-128843 – volume: 18 start-page: 21 year: 2005 ident: 10.1016/j.soncn.2019.08.002_bib0002 article-title: Edward Jenner and the history of smallpox and vaccination publication-title: Proc (Bay Univ Med Cent) – volume: 32 start-page: 231 year: 2005 ident: 10.1016/j.soncn.2019.08.002_bib0010 article-title: Interferon gamma and cancer immunoediting publication-title: Immunol Res doi: 10.1385/IR:32:1-3:231 – volume: 27 start-page: 5868 year: 2008 ident: 10.1016/j.soncn.2019.08.002_bib0016 article-title: Cancer and the immune system: an overview publication-title: Oncogene doi: 10.1038/onc.2008.277 – volume: 3 start-page: 388 year: 2013 ident: 10.1016/j.soncn.2019.08.002_bib0030 article-title: The basic principles of chimeric antigen receptor design publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0548 – volume: 116 start-page: 180 year: 1976 ident: 10.1016/j.soncn.2019.08.002_bib0023 article-title: Intracavity Bacillus Calmette-Guerin in the treatment of superficial bladder tumors publication-title: J Urol doi: 10.1016/S0022-5347(17)58737-6 – start-page: 193 year: 2017 ident: 10.1016/j.soncn.2019.08.002_bib0009 article-title: The immunobiology of cancer: from tumor escape to cancer immunoediting towards immunotherapy in gynecologic oncology – volume: 368 start-page: 1509 year: 2013 ident: 10.1016/j.soncn.2019.08.002_bib0033 article-title: Chimeric antigen receptor–modified T cells for acute lymphoid leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1215134 – volume: 161 start-page: 96 year: 2014 ident: 10.1016/j.soncn.2019.08.002_bib0024 article-title: From the discovery of monoclonal antibodies to their therapeutic application: an historical appraisal publication-title: Immunol Lett doi: 10.1016/j.imlet.2014.05.010 – volume: 158 start-page: 175 year: 1908 ident: 10.1016/j.soncn.2019.08.002_bib0006 article-title: The treatment of sarcoma with the mixed toxins of erysipelas and bacillus prodigiosus publication-title: Boston Medical and Surgical Journal doi: 10.1056/NEJM190802061580601 – volume: 2 start-page: 9 year: 2017 ident: 10.1016/j.soncn.2019.08.002_bib0004 article-title: Immunotherapy: exploring the state of the science publication-title: Clin J Oncol Nurs doi: 10.1188/17.CJON.S2.9-12 – volume: 42 start-page: 523 year: 2015 ident: 10.1016/j.soncn.2019.08.002_bib0012 article-title: Cancer and the immune system: basic concepts and targets for intervention publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2015.05.003 – volume: 3 start-page: 250 year: 2017 ident: 10.1016/j.soncn.2019.08.002_bib0013 article-title: Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead publication-title: J Cancer Metastasis Treat doi: 10.20517/2394-4722.2017.41 – volume: 30 start-page: 658 year: 2012 ident: 10.1016/j.soncn.2019.08.002_bib0027 article-title: Oncolytic virotherapy publication-title: Nat Biotechnol doi: 10.1038/nbt.2287 – volume: 3 start-page: 991 year: 2002 ident: 10.1016/j.soncn.2019.08.002_bib0019 article-title: Cancer immunoediting: from immunosurveillance to tumor escape publication-title: Nature – volume: 39 start-page: 1 year: 2013 ident: 10.1016/j.soncn.2019.08.002_bib0015 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – volume: 21 start-page: 137 year: 2004 ident: 10.1016/j.soncn.2019.08.002_bib0018 article-title: The immunobiology of cancer immunosurveillance and immunoediting publication-title: Immunity doi: 10.1016/j.immuni.2004.07.017 – volume: 7 start-page: 16 year: 2018 ident: 10.1016/j.soncn.2019.08.002_bib0028 article-title: The emerging role of oncolytic virus therapy against cancer publication-title: Chin Clin Oncol doi: 10.21037/cco.2018.04.04 – volume: 29 start-page: 1169 year: 1962 ident: 10.1016/j.soncn.2019.08.002_bib0021 article-title: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance publication-title: J Natl Cancer Inst – volume: 20 start-page: 271 year: 2009 ident: 10.1016/j.soncn.2019.08.002_bib0007 article-title: Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2009.07.004 – volume: 168 start-page: 707 year: 2017 ident: 10.1016/j.soncn.2019.08.002_bib0008 article-title: Primary, adaptive, and acquired resistance to cancer immunity publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 6 start-page: 722 year: 2005 ident: 10.1016/j.soncn.2019.08.002_bib0011 article-title: A critical function for type I interferons in cancer immunoediting publication-title: Nat Immunol doi: 10.1038/ni1213 – volume: 144 start-page: 646 year: 2011 ident: 10.1016/j.soncn.2019.08.002_bib0014 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 271 start-page: 1734 year: 1992 ident: 10.1016/j.soncn.2019.08.002_bib0025 article-title: Enhancement of anti-tumor immunity by CTLA-4 blockade publication-title: Science doi: 10.1126/science.271.5256.1734 – volume: 107 start-page: 1373 year: 2016 ident: 10.1016/j.soncn.2019.08.002_bib0026 article-title: Oncolytic virus therapy: a new era of cancer treatment at dawn publication-title: Cancer Sci doi: 10.1111/cas.13027 – volume: 324 start-page: 1432 year: 2013 ident: 10.1016/j.soncn.2019.08.002_bib0001 article-title: Cancer Immunotherapy publication-title: Science doi: 10.1126/science.342.6165.1432 – volume: 13 start-page: 670 year: 2015 ident: 10.1016/j.soncn.2019.08.002_bib0003 article-title: Principles of immunotherapy publication-title: J Natl Comp Canc Netw doi: 10.6004/jnccn.2015.0199 – volume: 331 start-page: 1565 year: 2011 ident: 10.1016/j.soncn.2019.08.002_bib0035 article-title: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion publication-title: Science doi: 10.1126/science.1203486 – volume: 5 start-page: 29 year: 2009 ident: 10.1016/j.soncn.2019.08.002_bib0017 article-title: The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion publication-title: Am J Immunol doi: 10.3844/ajisp.2009.29.49 – volume: 9 start-page: 361 year: 2009 ident: 10.1016/j.soncn.2019.08.002_bib0022 article-title: Tumour necrosis factor and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc2628 – volume: 33 start-page: 540 year: 2015 ident: 10.1016/j.soncn.2019.08.002_bib0034 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2025 |
| SSID | ssj0029609 |
| Score | 2.6262121 |
| SecondaryResourceType | review_article |
| Snippet | This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.
Published... This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 150923 |
| SubjectTerms | Adaptive immunity Cancer immunotherapy History Humans Immune System - physiology Immunologic Factors - therapeutic use Immunotherapy - methods Immunotherapy history Innate immunity Neoplasms - immunology Neoplasms - therapy Oncology Nursing - methods |
| Title | Cancer and the Immune System: The History and Background of Immunotherapy |
| URI | https://dx.doi.org/10.1016/j.soncn.2019.08.002 https://www.ncbi.nlm.nih.gov/pubmed/31526550 https://www.proquest.com/docview/2292983857 |
| Volume | 35 |
| WOSCitedRecordID | wos000493279100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1878-3449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029609 issn: 0749-2081 databaseCode: AIEXJ dateStart: 19950201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DSZeEIyv8jEFCfFEqsRuapu3MXViqBQkWilvluM4EmNKu66dxn_PXWynncam8cBLFFl2k_iuP9_Zd78j5F3BtJWgKjFl3IKDwhEHiyrmWvSNKAuRlA1l_oiPxyLP5fdOZxRyYS5OeV2Ly0s5_6-ihjYQNqbO_oO42x-FBrgHocMVxA7XOwn-EOW4ERmJCSDWM5OHGAtHDuKolz5p8wtzO-AW00qwu8_KunLi-wNZSMALxg2SWW0cdZMPHFifIRUh_kOvFi3gT-Fhv-EzEO1xldObWw2pbIPWAjoKjKXoO47Rnv1Lm4dUx0DiVSfbwEcwP6XLL74G3W4X4aQHboZBYtpU9lyc63qlCqfz42_qaDoaqckwn7yfn8VYQwzP2n1BlS2yQ3kmAeN2Do6H-ZfWAUd2PXTAwysHFqom3u_ac2-yVG7yRBqLZPKIPPSuRHTgVOAx6dh6j-x-9cESe-S-3wl6Qo6dTkQg7ghEGzmdiJxOfIxAIyKvEU2XtUZEsyq6ohFPyfRoODn8HPsaGrEBNF7GAtbi5ihVFwawdwC-lGRlVmac6wKsR1ZVlmmpqUkNlSXlVsp-BT4DoH0JBhR7RrbrWW1fkCjLMl1WjFYD8NkFetaSJ4XlKROJSUzVJTTMlzKeYB7rnJyqEEl4oppJVjjJCqufJrRLPrSD5o5f5fbugyAI5U1EZ_opUKPbB74NYlMAoHgqpms7W50rSsFDEExkvEueO3m2b8JSrB6RJS_vMPoVebD-z7wm28vFyr4h98zF8uf5Yp9s8Vzse4X8Aywhmbw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+and+the+Immune+System%3A+The+History+and+Background+of+Immunotherapy&rft.jtitle=Seminars+in+oncology+nursing&rft.au=Abbott%2C+Maura&rft.au=Ustoyev%2C+Yelena&rft.date=2019-10-01&rft.issn=1878-3449&rft.eissn=1878-3449&rft.volume=35&rft.issue=5&rft.spage=150923&rft_id=info:doi/10.1016%2Fj.soncn.2019.08.002&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0749-2081&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0749-2081&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0749-2081&client=summon |